Basal cell cancer treatment. Therapeutic experience with vismodegib therapy
https://doi.org/10.21518/2079-701X-2018-10-42-48
Abstract
Most patients with basal cell cancer (BCC) can be cured if timely diagnosed. However approximately 1,3% of BCCs may develop into locally-advanced and sometimes even metastatic disease when local treatment options are limited and systemic therapy is warranted. Vismodegib was the first drug which demonstrated efficacy for the treatment of locally-advanced and metastatic BCC, inhibiting pathologically active Sonic Hedgehog (SHh) signaling pathway in tumor cells and preventing their uncontrolled proliferation.
About the Authors
N. N. Petenko
N.N.Blokhin National Medical Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
L. V. Demidov
N.N.Blokhin National Medical Cancer Research Centre, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Lewis KG and Weinstock MA. Nonmelanoma skin cancer mortality (1988-2000): the Rhode Island follow-back study. Arch Dermatol, 2004, 140(7): 837-42.
2. Lomas A, Leonardi-Bee J and Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol, 2012, 166(5): 1069-80.
3. Bichakjian CK, et al. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2016, 14(5): 574-97.
4. Trakatelli M et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol, 2014. 24(3): 312-29.
5. Wadhera A et al. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J, 2006, 12(5): 7.
6. Youssef KK et al., Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol, 2010, 12(3): 299-305.
7. Mohler J. Requirements for hedgehog, a segmental polarity gene, in patterning larval and adult cuticle of Drosophila. Genetics, 1988, 120(4): 1061-72.
8. Kasper M et al., Basal cell carcinoma – molecular biology and potential new therapies. J Clin Invest, 2012, 122(2): 455-63.
9. Saran A. Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol, 2010, 6(6): 1003-14.
10. Evans DG and Farndon PA. Nevoid Basal Cell Carcinoma Syndrome, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).
11. LoRusso PM et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res, 2011, 17(8): 2502-11.
12. Sekulic A et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med, 2012, 366(23): 2171-9.
13. Sekulic A et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer, 2017, 17(1): 332.
14. Basset-Seguin N et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer, 2017, 86: 334-348.
15. Ally MS et al. An investigator-initiated openlabel clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol, 2014, 71(5): 904-911 e1.
16. Sofen H et al. A phase II, multicenter, openlabel, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol, 2015, 73(1): 99-105 e1.
17. Kish T and Corry L. Sonidegib (Odomzo) for the Systemic Treatment of Adults With Recurrent, Locally Advanced Basal Cell Skin Cancer. P T, 2016, 41(5): 322-5.
18. Nicolas M et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet, 2003, 33(3): 416-21.
19. Yang, SH et al. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. Nat Genet, 2008, 40(9): 1130-5.
20. Lipson EJ et al. Basal cell carcinoma: PD-L1/ PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer, 2017, 5: 23.
Review
For citations:
Petenko NN, Demidov LV. Basal cell cancer treatment. Therapeutic experience with vismodegib therapy. Meditsinskiy sovet = Medical Council. 2018;(10):42-48. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-42-48
Views:
799
Email this article 